---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-025657"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:13:34.618402+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Innoviva to acquire La Jolla Pharmaceutical for $6.23/share in cash, ~$149M EV

## Summary
- Offer price $6.23/share ($5.95 base + $0.28 from non-core asset sale); 70% premium to 30-day VWAP.
- Implied enterprise value approximately $149 million; tender offer expected within ~30 business days.
- Adds GIAPREZA (angiotensin II) and XERAVA (eravacycline) to Innoviva's infectious disease portfolio.
- Stockholders holding ~40% of La Jolla shares signed support agreement to tender shares.
- Transaction unanimously approved by both boards; subject to majority tender and other customary conditions.

## SEC filing metadata
- accession: 0001140361-22-025657
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/0001140361-22-025657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-025657
- JSON: https://secwatch.observer/filing/0001140361-22-025657.json
- Plain text: https://secwatch.observer/filing/0001140361-22-025657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.